Further studies are awaited in order to confirm our findings, and to verify whether inhibiting LAL ubiquitination or replacing LAL activity may prove beneficial effects in the treatment of NAFLD. This evidence concerns the gene LIPA and metabolic dysfunction-associated steatotic liver disease.